Literature DB >> 19080722

How do you treat patients with myalgia who take statins?

Saadi A Siddiqi1, Paul D Thompson.   

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are safe and effective in lowering low-density lipoprotein cholesterol. As a result, they confer an all-cause mortality benefit across a wide range of patient groups. The utility of statins is limited by their adverse effects, including myalgias and rhabdomyolysis. These clinical events, plus other symptoms, constitute what is termed statin myopathy. This review summarizes current concepts of statin myopathy and presents strategies to minimize statin-associated myopathic complaints.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19080722     DOI: 10.1007/s11883-009-0002-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  36 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

2.  An assessment of statin safety by muscle experts.

Authors:  Paul D Thompson; Priscilla M Clarkson; Robert S Rosenson
Journal:  Am J Cardiol       Date:  2006-02-09       Impact factor: 2.778

3.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Authors:  James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Journal:  Am J Cardiol       Date:  2006-02-28       Impact factor: 2.778

4.  Statin myopathy: incidence, risk factors, and pathophysiology.

Authors:  Kimberly A Sewright; Priscilla M Clarkson; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

5.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

Review 6.  Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Authors:  Amir Kashani; Christopher O Phillips; JoAnne M Foody; Yongfei Wang; Sandeep Mangalmurti; Dennis T Ko; Harlan M Krumholz
Journal:  Circulation       Date:  2006-12-11       Impact factor: 29.690

Review 7.  The myopathy of statins.

Authors:  Miroslaw Smogorzewski
Journal:  J Ren Nutr       Date:  2005-01       Impact factor: 3.655

8.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

9.  Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.

Authors:  Theunis C Goosen; Jonathan N Bauman; John A Davis; Chongwoo Yu; Susan I Hurst; J Andrew Williams; Cho-Ming Loi
Journal:  Drug Metab Dispos       Date:  2007-04-30       Impact factor: 3.922

10.  Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.

Authors:  Giuseppe Caso; Patricia Kelly; Margaret A McNurlan; William E Lawson
Journal:  Am J Cardiol       Date:  2007-04-03       Impact factor: 2.778

View more
  3 in total

Review 1.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

2.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

3.  A small-molecule screening strategy to identify suppressors of statin myopathy.

Authors:  Bridget K Wagner; Tamara J Gilbert; Jun-ichi Hanai; Shintaro Imamura; Nicole E Bodycombe; Robin S Bon; Herbert Waldmann; Paul A Clemons; Vikas P Sukhatme; Vamsi K Mootha
Journal:  ACS Chem Biol       Date:  2011-07-15       Impact factor: 5.100

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.